FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How to Clean Your Home When Caring for Someone With Cancer October 7, 2020 American tobacco company Philip Morris International offers £1bn for UK pharma... July 9, 2021 Cern και αντιμετώπιση του καρκίνου June 9, 2019 Beating the Heat with Beets July 31, 2020 Load more HOT NEWS FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... Breast Cancer Patients With Anxiety or Depression More Prone to Opioid... Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer
